Selected article for: "action mechanism and lung inflammatory"

Author: Niu, Yaoyun; Chen, Yang; Sun, Pengbo; Wang, Yangyang; Luo, Jingyi; Ding, Yipei; Xie, Weidong
Title: Intragastric and atomized administration of canagliflozin inhibit inflammatory cytokine storm in lipopolysaccharide-treated sepsis in mice: a potential COVID-19 treatment
  • Cord-id: yxnd9ebm
  • Document date: 2021_5_9
  • ID: yxnd9ebm
    Snippet: To date, drugs to attenuate cytokine storm in severe cases of Corona Virus Disease 2019 (COVID-19) are not available. In this study, we investigated the effects of intragastric and atomized administration of canagliflozin (CAN) on cytokine storm in lung tissues of lipopolysaccharides (LPS)-induced mice. Results showed that intragastric administration of CAN significantly and widely inhibited the production of inflammatory cytokines in lung tissues of LPS-induced sepsis mice. Simultaneously, intr
    Document: To date, drugs to attenuate cytokine storm in severe cases of Corona Virus Disease 2019 (COVID-19) are not available. In this study, we investigated the effects of intragastric and atomized administration of canagliflozin (CAN) on cytokine storm in lung tissues of lipopolysaccharides (LPS)-induced mice. Results showed that intragastric administration of CAN significantly and widely inhibited the production of inflammatory cytokines in lung tissues of LPS-induced sepsis mice. Simultaneously, intragastric administration of CAN significantly improved inflammatory pathological changes of lung tissues. Atomized administration of CAN also exhibited similar effects in LPS-induced sepsis mice. Furthermore, CAN significantly inhibited hypoxia inducible factor 1α (HIF-1α) and phosphofructokinase-2/fructose-2,6-bisphosphatase 3 (PFKFB3) protein levels in LPS-treated lung tissues. These results indicated that CAN might attenuate cytokine storm and reduce the inflammatory symptoms in critical cases in COVID-19. Its action mechanism might involve the regulation of HIF-1α and glycolysis in vivo. However, further studies about clinical application and mechanism analysis should be validated in the future.

    Search related documents:
    Co phrase search for related documents
    • action mechanism and acute treatment: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • action mechanism and long administration: 1, 2, 3
    • action mechanism and long term administration: 1, 2
    • action mechanism and low molecular weight: 1, 2
    • action mechanism and lps control: 1
    • action mechanism and lps induce: 1
    • action mechanism and lung infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • action mechanism and lung inflammation: 1, 2, 3, 4, 5, 6, 7
    • action mechanism and lung inflammatory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • action mechanism and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29
    • action mechanism and lung tissue: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • action mechanism and lung tissue injury: 1, 2
    • action mechanism and lung weight: 1, 2, 3, 4
    • action mechanism and lung weight index: 1, 2
    • action mechanism and lung weight index inhibit: 1
    • action mechanism and lung weight ratio: 1, 2
    • action mechanism and lung weight significantly increase: 1